OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.
By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.
5-amino-1-methylquinolinium. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Low reported | 50 mg | 1× daily | 0.5 mL | 50 u | 1 doses | |
| Standard | 100 mg | 1× daily | 1 mL | 100 u | — doses | |
| Upper reported | 150 mg | 1× daily | 1.5 mL | 150 u ⚠ | — doses |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial | |
|---|---|---|---|---|---|---|
| Weeks 1–2 | 50 mg | daily | 0.5 mL | 50 u | 14 | 700 mg |
| Weeks 3–4 | 100 mg | daily | 1 mL | 100 u | 14 | 1400 mg |
| Week 5 onward per 4 weeks from here on |
150 mg | daily | 1.5 mL | 150 u ⚠ | 28 | 4200 mg |
A small-molecule NNMT inhibitor rather than a true peptide. Research data show reduced adiposity in diet-induced obesity models. No human trials. Commonly grouped with the peptides even though it is a different class of molecule.
Buy 5-Amino-1MQthis peptideOpens optimal-pep.com in a new tab
Browse the full catalogue, or jump to a neighbouring compound.
A C-terminal fragment of human growth hormone investigated as an anti-obesity agent. Human trials were conducted, but efficacy on …
An estrogen-related receptor pan-agonist described as an exercise mimetic in preclinical models. Not a peptide, no human data of a…
Every compound compared in one table: dose range, how often, half-life and evidence tier.